Analysis of immunoglobulins reactive to CTL epitopes peptides

• Project/Area Number: 24791452
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Kurume University
• Principal Investigator: MATSUEDA Satoko 久留米大学, がんワクチンセンター, 講師 (60610582)
• Project Period (FY): 2012-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: 抗ペプチド抗体 / がん / ペプチド / 生命予後 / バイオマーカー / 腫瘍関連抗原 / 免疫能解析

Research Abstract

We assessed immunoglobulins reactive to CTL epitopes peptides derived from tumor-associated antigens in healthy donors and cancer patients. The sum of immunoglobulins reactive CTL epitopes peptides were well correlated with better overall survival in cancer patients. Our results suggested that measurement of immunoglobulins specific to CTL epitope peptides may provide a new biomarker for overall survival of patients with cancer. From this analysis of anti-peptide antibodies in vitro and vivo, we found that immunoglobulins specific to CTL epitope peptide may play a roll to enhance and induce tumor antigen specific cytotoxic T cells.

Research Products

• [Journal Article] Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. (2013)
  • Author(s): Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, Yamada S, Seki R, Yutani S, Shichijo S, Mine T, Fukuda T, Okamura T, Okuda S, Sata M, Honda J, Kaji M, Itoh K, Sasada T.
  • Journal Title: Dev Comp Immunol. Volume: 41(1) Issue: 1 Pages: 68-76
  • DOI: 10.1016/j.dci.2013.04.004
  • Peer Reviewed
• [Journal Article] Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. (2013)
  • Author(s): Yutani S, Komatsu N, Matsueda S, Yoshitomi M, Shirahama T, Yamada A, Itoh K, Sasada T.
  • Journal Title: Evid Based Complement Alternat Med. Volume: 2013 Pages: 981717-981717
  • DOI: 10.1155/2013/981717
  • Peer Reviewed
• [Presentation] Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans : A new biomarker for overall survival of patients with malignant diseases (2013)
  • Author(s): Matsueda S, Komatsu N, Kusumoto K, Koga S, Yutani S, Shichijo S, Mine T, Itoh K, Sasada T
  • Organizer: The Cancer Vaccine Institute's International Symposium on Immunotherapy
  • Place of Presentation: イギリス・ロンドン
• [Presentation] Humoral immune responses to CTL epitope peptides from tumor-associated antigens are are widely detectable in humans (2013)
  • Author(s): Satoko Matsueda, Nobukazu Komatsu, Kenichi Kusumoto, Shintaro Koga, Shigeru Yutani, Shigeki Shichijo, Takashi Mine, Kyogo Itoh, Tetsuro Sasada
  • Organizer: The Cancer Vaccine Institute's International Symposium on Immunotherapy
  • Place of Presentation: 英国、ロンドン
• [Presentation] Antibodies against CTL epitopes from tumor-associated antigens are widely detectable in humans (2012)
  • Author(s): Satoko Matsueda, Nobukazu Komatsu, Kenichi Kusumoto, Shintaro Koga, Shigeru Yutani, Shigeki Shichijo, Takashi Mine, Kyogo Itoh, Tetsuro Sasada
  • Organizer: 癌学会
  • Place of Presentation: 札幌